Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Health Sciences Council’s Panel Approves Basic Framework for “Guidelines,” “Plans” for COI Management in “Specified Clinical Research”
November 20, 2017
- MHLW Panel to Continue Discussions on Inclusion of Zoster and Trivalent Vaccines in Public Vaccination Programs
November 20, 2017
- LDP Lawmakers Air Concerns over Govt’s Drug Pricing Plans: Social Security Taskforce
November 20, 2017
- Govt Plans to Apply 5 Price Bands for Listed Generics in “Off-Year” Revisions, Maintain 50% Rule for 1st Generics in April
November 20, 2017
- MHLW Panel Members Call for Tougher Regulations on Drug Rep Activities
November 17, 2017
- Annual Re-Pricing Likely to Start in FY2021 for Scope of Products Defined in 2020
November 17, 2017
- Govt Plans Tiered PMP for Smaller Scope of Products, Post-Z2 Rule for LLPs
November 17, 2017
- MHLW to Launch Study on Leftover Vial Drugs
November 16, 2017
- LDP Study Group on Pharma Policies Submits Resolution to Health Minister
November 16, 2017
- MHLW to Issue Optimal Use Guidelines for Bavencio
November 16, 2017
- Chuikyo OKs Bavencio, Maviret, Ibrance and More for Listing on Nov. 22
November 15, 2017
- Industry Opposes Full Annual Price Revisions at LDP Hearing
November 15, 2017
- MHLW Counterfeit Drug Panel Agrees on “Voluntary” Introduction of GDP in Japan
November 14, 2017
- Benralizumab, Olaparib, Keytruda’s Urothelial Carcinoma Use Up for MHLW Panel Review/Report on Nov. 24
November 13, 2017
- Pilot CEA Program: Company Data, Third-Party Re-Analysis Data Show Big Gaps for Some Products
November 13, 2017
- Dispensing of Generics Down Slightly Despite Increase in Generic-Name Prescribing: Chuikyo Survey
November 13, 2017
- Japan, US Agree to Extend Chuikyo’s Industry Hearing Time
November 9, 2017
- 3rd-Party Re-Analysis Now Complete; Chuikyo Discusses Pilot CEA Products Closed Door
November 9, 2017
- Driver Gene-Based Drug Discovery Also Applicable for Early Approval System: MHLW
November 8, 2017
- 3 Japanese Plasma Fraction Product Makers Raise Concerns about Low NHI Prices at MHLW Panel
November 8, 2017
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…